Clovis Oncology (Clovis Oncology) GF Value Rank : 0 (As of Apr. 27, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology GF Value Rank?

Clovis Oncology has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Clovis Oncology GF Value Rank Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Clovis Oncology (Clovis Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301

Website

https://www.clovisoncology.com

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.

Executives

Thomas C. Harding	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read	officer: See Remarks	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl	officer: See remarks	5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov	director	1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair	director	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy	director, officer: President and CEO	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen	director	TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair	director	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein	director	428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham	director	AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104